403 related articles for article (PubMed ID: 17943030)
41. Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia.
Yohanna D; Cifu AS
JAMA; 2017 Sep; 318(11):1057-1058. PubMed ID: 28975291
[No Abstract] [Full Text] [Related]
42. Atypical antipsychotics in the elderly: a review of therapeutic trends and clinical outcomes.
Burke AD; Tariot PN
Expert Opin Pharmacother; 2009 Oct; 10(15):2407-14. PubMed ID: 19663744
[TBL] [Abstract][Full Text] [Related]
43. Are there any news about the antipsychotic medications in the elderly?
Cucinotta D; Minardi M; Lanfranchi G; Reggiani A; Savorani G
Arch Gerontol Geriatr; 2007; 44 Suppl 1():133-7. PubMed ID: 17317446
[TBL] [Abstract][Full Text] [Related]
44. Antipsychotic use in dementia: the relationship between neuropsychiatric symptom profiles and adverse outcomes.
Mueller C; John C; Perera G; Aarsland D; Ballard C; Stewart R
Eur J Epidemiol; 2021 Jan; 36(1):89-101. PubMed ID: 32415541
[TBL] [Abstract][Full Text] [Related]
45. The expert consensus guideline series. Treatment of dementia and its behavioral disturbances.
Expert Consensus Panel for Dementia
Postgrad Med; 2005 Jan; Spec No():1-111. PubMed ID: 17203560
[No Abstract] [Full Text] [Related]
46. Valproate in the treatment of behavioral agitation in elderly patients with dementia.
Lott AD; McElroy SL; Keys MA
J Neuropsychiatry Clin Neurosci; 1995; 7(3):314-9. PubMed ID: 7580190
[TBL] [Abstract][Full Text] [Related]
47. The modern role of antipsychotics for the treatment of agitation and psychosis in Alzheimer's disease.
Creese B; Da Silva MV; Johar I; Ballard C
Expert Rev Neurother; 2018 Jun; 18(6):461-467. PubMed ID: 29764230
[TBL] [Abstract][Full Text] [Related]
48. Risks and benefits of antipsychotic drugs in elderly patients with dementia.
Howland RH
J Psychosoc Nurs Ment Health Serv; 2008 Nov; 46(11):19-23. PubMed ID: 19051574
[TBL] [Abstract][Full Text] [Related]
49. Agitation. How to manage behavior disturbances in the older patient with dementia.
Neugroschl J
Geriatrics; 2002 Apr; 57(4):33-7; quiz 40. PubMed ID: 11974389
[TBL] [Abstract][Full Text] [Related]
50. [Treatment of behavioral abnormalities in patients with dementia].
Wolf H; Gertz HJ
MMW Fortschr Med; 2004 Jun; 146(24):43-5. PubMed ID: 15366492
[TBL] [Abstract][Full Text] [Related]
51. Use of drugs by Old Age Psychiatrists in the treatment of psychotic and behavioural symptoms in patients with dementia.
Condren RM; Cooney C
Aging Ment Health; 2001 Aug; 5(3):235-41. PubMed ID: 11575062
[TBL] [Abstract][Full Text] [Related]
52. Outcomes of antipsychotic drug use in community-dwelling elders with dementia.
Kolanowski A; Fick D; Waller JL; Ahern F
Arch Psychiatr Nurs; 2006 Oct; 20(5):217-25. PubMed ID: 17010825
[TBL] [Abstract][Full Text] [Related]
53. [Expert opinion on APAP (prolonged action atypical antipsychotic agents). How to prescribe an APAP?].
Dassa D; Lacambre M; Vacheron MN
Encephale; 2009 Jan; Suppl 3():S109-13. PubMed ID: 19268179
[No Abstract] [Full Text] [Related]
54. Pharmacological treatment of psychosis and agitation in elderly patients with dementia: four decades of experience.
Kindermann SS; Dolder CR; Bailey A; Katz IR; Jeste DV
Drugs Aging; 2002; 19(4):257-76. PubMed ID: 12038878
[TBL] [Abstract][Full Text] [Related]
55. Pharmacological treatment of Alzheimer's dementia: state of the art and current dilemmas.
Omerovic M; Hampel H; Teipel SJ; Buerger K
World J Biol Psychiatry; 2008; 9(1):69-75. PubMed ID: 17886162
[TBL] [Abstract][Full Text] [Related]
56. [Cerebral infarct and atypical antipsychotic agents].
Lacomblez L
Psychol Neuropsychiatr Vieil; 2004 Dec; 2(4):299. PubMed ID: 15706675
[No Abstract] [Full Text] [Related]
57. Introduction: the clinical impact of agitation in various psychiatric disorders: management consensus and controversies.
Mintzer JE
J Clin Psychiatry; 2006; 67 Suppl 10():3-5. PubMed ID: 16965189
[No Abstract] [Full Text] [Related]
58. [Pro and contra: basic precedence of atypical neuroleptics].
Naber D; Dose M
Psychiatr Prax; 2005 May; 32(4):163-6. PubMed ID: 15852207
[No Abstract] [Full Text] [Related]
59. Discontinuation of risperidone in Alzheimer's disease.
Ling SM; Bonner AF; McMullen TL
N Engl J Med; 2013 Jan; 368(2):187. PubMed ID: 23301740
[No Abstract] [Full Text] [Related]
60. Discontinuation of risperidone in Alzheimer's disease.
Power GA
N Engl J Med; 2013 Jan; 368(2):186-7. PubMed ID: 23301739
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
